GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (NYSE:LH) » Definitions » Cyclically Adjusted PS Ratio

Labcorp Holdings (Labcorp Holdings) Cyclically Adjusted PS Ratio : 1.47 (As of May. 26, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Labcorp Holdings's current share price is $199.65. Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $136.09. Labcorp Holdings's Cyclically Adjusted PS Ratio for today is 1.47.

The historical rank and industry rank for Labcorp Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

LH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.08   Med: 1.88   Max: 2.52
Current: 1.47

During the past years, Labcorp Holdings's highest Cyclically Adjusted PS Ratio was 2.52. The lowest was 1.08. And the median was 1.88.

LH's Cyclically Adjusted PS Ratio is ranked better than
67.16% of 134 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.38 vs LH: 1.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Labcorp Holdings's adjusted revenue per share data for the three months ended in Mar. 2024 was $37.504. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $136.09 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Labcorp Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Labcorp Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings Cyclically Adjusted PS Ratio Chart

Labcorp Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 1.84 2.47 1.65 1.72

Labcorp Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 1.61 1.53 1.72 1.61

Competitive Comparison of Labcorp Holdings's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Labcorp Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's Cyclically Adjusted PS Ratio falls into.



Labcorp Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Labcorp Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=199.65/136.09
=1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Labcorp Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=37.504/131.7762*131.7762
=37.504

Current CPI (Mar. 2024) = 131.7762.

Labcorp Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 17.571 100.560 23.026
201409 17.940 100.428 23.540
201412 17.569 99.070 23.369
201503 19.117 99.621 25.287
201506 22.138 100.684 28.974
201509 22.520 100.392 29.560
201512 22.270 99.792 29.408
201603 22.813 100.470 29.921
201606 23.350 101.688 30.259
201609 23.019 101.861 29.779
201612 22.366 101.863 28.934
201703 23.142 102.862 29.647
201706 24.380 103.349 31.086
201709 25.279 104.136 31.989
201712 26.417 104.011 33.469
201803 27.546 105.290 34.475
201806 27.828 106.317 34.492
201809 27.569 106.507 34.110
201812 27.572 105.998 34.277
201903 28.052 107.251 34.467
201906 29.167 108.070 35.565
201909 29.791 108.329 36.239
201912 30.137 108.420 36.629
202003 29.051 108.902 35.153
202006 28.340 108.767 34.335
202009 39.716 109.815 47.659
202012 45.674 109.897 54.767
202103 42.249 111.754 49.818
202106 39.111 114.631 44.961
202109 41.839 115.734 47.638
202112 11.125 117.630 12.463
202203 41.485 121.301 45.068
202206 31.545 125.017 33.251
202209 31.607 125.227 33.260
202212 32.844 125.222 34.563
202303 34.133 127.348 35.320
202306 34.047 128.729 34.853
202309 35.136 129.860 35.655
202312 35.477 129.419 36.123
202403 37.504 131.776 37.504

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Labcorp Holdings  (NYSE:LH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Labcorp Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Labcorp Holdings (Labcorp Holdings) Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Executives
Peter J Wilkinson officer: SVP, Chief Accounting Officer C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson director WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D officer: SVP, Global General Counsel 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman director 6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber officer: CEO, Covance Drug Development 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder officer: EVP, President-Diagnostics Lab 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey officer: EVP, Chief Strategy Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo officer: EVP, Pres, Central Labs & Intl 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham officer: EVP, CHRO C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike officer: Pres & CEO Clinical Business C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg officer: Chief Financial Officer, EVP P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney officer: SVP, Chief Medical Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams director DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy officer: EVP, Chief Marketing Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215